Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial

BACKGROUND: Vinorelbine constitutes effective chemotherapy for metastatic breast cancer (MBC) and acts synergistically with trastuzumab in HER-2/neu positive disease. The present study was set out to evaluate the efficacy and safety of vinorelbine when combined with lapatinib, an anti-HER2 tyrosine-...

Descripción completa

Detalles Bibliográficos
Autores principales: Thallinger, Christiane, Lang, Istvan, Kuhar, Cvetka Grasic, Bartsch, Rupert, Singer, Christian F., Petruzelka, Lubos, Melichar, Bohuslav, Knittelfelder, Regina, Brodowicz, Thomas, Zielinski, Christoph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758093/
https://www.ncbi.nlm.nih.gov/pubmed/26887956
http://dx.doi.org/10.1186/s12885-016-2171-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4758093/
https://www.ncbi.nlm.nih.gov/pubmed/26887956
http://dx.doi.org/10.1186/s12885-016-2171-y

Ejemplares similares